"Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention. Maybe less is more?

American Heart Journal

Volumn 152, Issue 5, 2006, Pages 812-814

  Fischell, Tim A ^a  

^a Borgess Heart Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THIENO[3,2 C]PYRIDINE DERIVATIVE;

BLEEDING; CLINICAL TRIAL; CORONARY STENT; COST CONTROL; DRUG MEGADOSE; DRUG POTENCY; EDITORIAL; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY STENOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS;

EID: 33750383027     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.06.029     Document Type: Editorial

References (15)

1. Lange R.A., and Hillis L.D. Antiplatelet therapy for ischemic heart disease. N Engl J Med 350 (2004) 277-280
2. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
3. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrelin to Minimize Platelet Aggregation and Coronary Thrombosis-II. Lancet 349 (1997) 1422-1428
4. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
5. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
6. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
7. Marmur J.D., Mitre C.A., Barnathan E.S., et al. Benefit of bolus-only glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the epic trial. Am H Journal (2006) [need data from editors]
8. Steinhubl S.R., Berger P.B., Brennan D., and for the CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. Circulation 47 (2006) 939-943
9. Steinhubl S.R., Berger P.B., Mann III T., and for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288 (2002) 2411-2420 [Circulation 2006;47:939-43]
10. Gilchrist I.C., O'Shea J.C., Kosoglou T., et al. Pharmacodynamics and pharmacokinetics of higher-dose double-bolus eptifibitide in percutaneous coronary intervention. Circulation 104 (2001) 406-411
11. Kini A.S., Richard M., Suleman J., et al. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). J Am Coll Cardiol 90 (2002) 526-529
12. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
13. Fischell T.A., Attia T.A., Rane S.G., et al. High dose, single-bolus eptifibatide is effective in preventing non-Q wave myocardial infarction with minimal bleeding complications in elective coronary stenting. [abstract]. Am J Cardiol (2005) [TCT-Abstracts, 153-H]
14. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
15. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800